Table 1.
List of all drugs targeting specific molecular pathways which, according to Clinicaltrials.gov, were tested at least one time in clinical trials for pancreatic cancer treatment and that gave results. None of them significantly improve the standard treatments.
| Name | Alias | Molecular target | Pathway | Type |
|---|---|---|---|---|
| Aflibercept | L01XX44 | VEGF | VEGF sign | rp |
| Alisertib | MLN-8237 | AURKA | Cell cycle | i |
| Alvocidib | L86-8275 | CDK9 | Cell cycle | i |
| Apatorsen | OGX-427 | HSP27 | Proteostasis | as |
| Apricoxib | nd | COX-2 | Multiple | i |
| Axitinib | AG-013736 | VEGFR | VEGF sign | i |
| Bevacizumab | Avastin | VEGF | VEGF sign | ab |
| Bortezomib | PS-341 | Proteasome | Proteostasis | i |
| Bosutinib | SKI-606 | BCR-ABL + SRC family | Multiple | i |
| Bryostatin-1 | nd | PKC | PKC | i |
| Cabozantinib | XL-184 | HGFR + AXL + VEGFR | Multiple | i |
| Cetuximab | BMS 564717 | EGFR | EGF sign | ab |
| Cixutumumab | IMC-A12 | IGF-1R | PI3K/AKT | ab |
| Dactolisib | BEZ235 | PI3K | mTOR | i |
| Dasatinib | BMS-354825 | BCR-ABL, SRC family, c-KIT, EPHA2, PDGFRb | Multiple | i |
| Demcizumab | OMP-21M18 | DLL4 | Notch sign | ab |
| Erlotinib | L01XE03 | EGFR | EGF sign | i |
| Etanercept | GP-2015 | TNF α | TNF sign | ab |
| Everolimus | RAD001 | mTORC1 | mTOR | i |
| Galunisertib | (LY2157299) | TGF-beta-R1 | TGF-beta sign | i |
| Ganetespib | (STA-9090) | HSP90 | Proteostasis | i |
| Ganitumab | AMG 479 | IGF1-1-R | PI3K/AKT | ab |
| Imatinib | STI571 | BCR-ABL, c-KIT, PDGFR, DDR1/2, CSF1R | Multiple | i |
| Ipilimumab | MDX-010 | CTLA-4 | T-Lymphocyte activation | ab |
| Lapatinib | gw572016 | EGFR | EGF sign | i |
| Motesanib | AMG 706 | VEGFR | VEGF sign | i |
| nd | PF-00562271 | FAK | Adhesion/invasion | i |
| nd | MK-2206 | AKT1/2/3 | PI3K/AKT | i |
| nd | RO4929097 | Gamma-secretase | Notch sign | i |
| Olaparib | AZD-2281 | PARP | DNA repair | i |
| Panitumumab | ABX-EGF | EGFR | EGF sign | ab |
| Panobinostat | nd | HDAC | Multiple | i |
| Pazopanib | GW-786034 | VEGFR | VEGF sign | i |
| pertuzumab | R1273 | HER2 | EGF sign | ab |
| Pimasertib | AS-703026 | MEK1/2 | MAP kinase | i |
| Rabusertib | LY2603618 | CHK1 | Cell cycle | i |
| RAV12 | RAAG12 | Sodium channels (via N-linked carbohydrate antigen) | Cell homeostasis | ab |
| Romidepsin | FK-228 | HDAC | Multiple | i |
| Ruxolitinib | INC424 | JAK1/2 | JAK-STAT | i |
| Saracatinib | AZD0530 | SRC family | SRC | i |
| Selumetinib | AZD6244 | MEK1/2 | MAP kinase | i |
| Sirolimus | Rapamycin | mTORC1/2 (via FKBP12) | mTOR | i |
| Sorafenib | BAY-43-9006 | VEGFR, PDGFR and Raf family kinases | Multiple | i |
| Sunitinib | SU-011248 | RTKs | Multiple | i |
| Tanespimycin | 17-AAG | HSP90 | Proteostasis | i |
| Temsirolimus | CCI-779 | mTOR | mTOR | i |
| Trametinib | GSK1120212 | MEK1/2 | MAP kinase | i |
| Vatalanib | PTK787 | VEGFR, c-KIT | Multiple | i |
| Vismodegib | RG-3616 | SMO (smoothened receptor) | Hedgehog sign | i |
| Vorinostat | MK-0683 | HDAC | Multiple | i |
ab: antibody; as: antisens; i: inhibitor, rp: recombinant protein.